ECSP24002381A - Proteínas actrii y usos de las mismas - Google Patents

Proteínas actrii y usos de las mismas

Info

Publication number
ECSP24002381A
ECSP24002381A ECSENADI20242381A ECDI202402381A ECSP24002381A EC SP24002381 A ECSP24002381 A EC SP24002381A EC SENADI20242381 A ECSENADI20242381 A EC SENADI20242381A EC DI202402381 A ECDI202402381 A EC DI202402381A EC SP24002381 A ECSP24002381 A EC SP24002381A
Authority
EC
Ecuador
Prior art keywords
pulmonary
lung disease
disease
hypertension associated
pulmonary hypertension
Prior art date
Application number
ECSENADI20242381A
Other languages
English (en)
Inventor
Patrick Andre
Ravindra Kumar
Gang Li
Original Assignee
Acceleron Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc
Publication of ECSP24002381A publication Critical patent/ECSP24002381A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En algunos aspectos, la divulgación se refiere a composiciones y métodos que comprenden polipéptidos de ActRII para tratar, prevenir o reducir la tasa de progresión y/o la gravedad de la hipertensión pulmonar asociada con la enfermedad pulmonar (p. ej., la hipertensión pulmonar asociada con la enfermedad pulmonar obstructiva crónica (EPOC), la enfermedad pulmonar intersticial (EPI) o la combinación de fibrosis pulmonar y enfisema (CFPE)), en particular para tratar, prevenir o reducir la tasa de progresión y/o la gravedad de una o más complicaciones asociadas con hipertensiones pulmonares asociadas con la enfermedad pulmonar (p. ej., la hipertensión pulmonar asociada con la enfermedad pulmonar obstructiva crónica (EPOC), la enfermedad pulmonar intersticial (EPI) o la combinación de fibrosis pulmonar y enfisema (CFPE)).
ECSENADI20242381A 2021-06-11 2024-01-11 Proteínas actrii y usos de las mismas ECSP24002381A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163209871P 2021-06-11 2021-06-11

Publications (1)

Publication Number Publication Date
ECSP24002381A true ECSP24002381A (es) 2024-02-29

Family

ID=84426426

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI20242381A ECSP24002381A (es) 2021-06-11 2024-01-11 Proteínas actrii y usos de las mismas

Country Status (18)

Country Link
US (1) US20240277806A1 (es)
EP (1) EP4351626A4 (es)
JP (1) JP2024521575A (es)
KR (1) KR20240035445A (es)
CN (1) CN117794562A (es)
AU (1) AU2022289885A1 (es)
CA (1) CA3221581A1 (es)
CL (1) CL2023003659A1 (es)
CO (1) CO2024000079A2 (es)
CR (1) CR20240013A (es)
DO (1) DOP2023000269A (es)
EC (1) ECSP24002381A (es)
GE (1) GEAP202416434A (es)
IL (1) IL309100A (es)
JO (1) JOP20230321A1 (es)
MX (1) MX2023014761A (es)
PE (1) PE20242364A1 (es)
WO (1) WO2022261436A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4142769A4 (en) 2020-04-28 2024-05-15 Acceleron Pharma Inc. ACTRII PROTEINS AND USE IN THE TREATMENT OF POSTCAPILLARY PULMONARY HYPERTENSION

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3015277A1 (en) * 2016-03-10 2017-09-14 Acceleron Pharma Inc. Activin type 2 receptor binding proteins and uses thereof
CN116531490A (zh) * 2016-07-15 2023-08-04 阿塞勒隆制药公司 用于治疗肺高血压的组合物和方法
WO2019217715A1 (en) * 2018-05-09 2019-11-14 Keros Therapeutics, Inc. Activin receptor type iia variants and methods of use thereof
EP4054617A4 (en) * 2019-11-05 2023-12-27 Acceleron Pharma Inc. Treatments for systemic sclerosis

Also Published As

Publication number Publication date
JOP20230321A1 (ar) 2023-12-11
CN117794562A (zh) 2024-03-29
WO2022261436A3 (en) 2023-01-19
JP2024521575A (ja) 2024-06-03
CA3221581A1 (en) 2022-12-15
CL2023003659A1 (es) 2024-06-28
CO2024000079A2 (es) 2024-01-25
US20240277806A1 (en) 2024-08-22
AU2022289885A1 (en) 2024-01-18
KR20240035445A (ko) 2024-03-15
DOP2023000269A (es) 2024-04-30
IL309100A (en) 2024-02-01
CR20240013A (es) 2024-04-01
PE20242364A1 (es) 2024-12-16
MX2023014761A (es) 2024-01-19
EP4351626A2 (en) 2024-04-17
EP4351626A4 (en) 2025-04-16
WO2022261436A2 (en) 2022-12-15
GEAP202416434A (en) 2024-04-25

Similar Documents

Publication Publication Date Title
ECSP23004827A (es) Proteínas actrii para el tratamiento de la hipertensión pulmonar
CO2022016210A2 (es) Proteínas actrii y su uso en el tratamiento de la hipertensión pulmonar postcapilar
CL2012000063A1 (es) Polipéptido factor ix (fix) o un fragmento del mismo porque comprende la modificación de un aminoácido; vector; célula; método para expresar el polipéptido fix; composición farmacéutica; uso de la composición para tratar enfermedades trombóticas, hemorrágicas y coagulación intravascular diseminada (cid) (div. sol. 1796-07).
PH12017502286A1 (en) Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi)
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
DK1283735T3 (da) Fremgangsmåde til fremstilling af hydrazon-derivater
WO2015016761A8 (en) Mscs in the treatment of inflammatory pulmonary diseases
CO2024000079A2 (es) Proteínas actrii y usos de las mismas
WO2009011782A3 (en) METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR
NO20081354L (no) Dobbelt variabelt domeneimmunoglobin samt fremgangsmater derav
CL2011003273A1 (es) Antígeno del virus respiratorio sincicial (vrs) recombinante, que comprende un polipéptido de proteína f soluble con una modificación que altera su glicosilación y que a su vez comprende un dominio f1 y un dominio f2 de proteína f de vrs; composición inmunogénica que lo comprende; ácido nucleico que lo codifica; vector; célula hospedera; método para producir dicho antígeno del vrs; y su uso para tratar una infección de vrs.
WO2008045346A3 (en) Recombinant modified vaccinia ankara encoding a her-2 antigen for use in treating cancer
NO20080718L (no) Preparat for behandling av oftalmiske lidelser via serumretinol, serumretinol-bindingsprotein (RBP) og/eller serumretinol-RBP-modulering
NO20062876L (no) Sammensetninger til kombinert radio- og kjemoterapi, og fremgangsmater
NO20084187L (no) Medikamenter og proteiner
EP3536794A3 (de) Peptide mit spezifität für die lunge
CL2022001035A1 (es) Composiciones y métodos para minimizar la pérdida de proteínas a concentraciones de proteínas bajas
AR101597A1 (es) Proteínas de fusión uti (inhibidor de tripsina urinaria)
PE20230090A1 (es) Anticuerpos contra el factor de las celulas madre y metodos de uso de ellos
CL2020000597A1 (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas.
WO2022192420A3 (en) Actrii proteins and uses thereof
WO2021231803A3 (en) Binding molecules for covid-19 treatment
WO2006105279A3 (en) Defective sindbis viral vectors
WO2022047225A3 (en) Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases
WO2007084964A3 (en) Pharmaceutical composition comprising a protein pump inhibitor and protein component